S. 932 explained · 119th Congress · Pending in Congress
Give Kids a Chance Act of 2025
Cosponsors: 20 (10 D, 10 R) · per Congress.gov, 2026-10-12
Introduced: 2025-03-11
Latest action (2025-03-11): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
What S. 932 does, in plain terms
Give Kids a Chance Act of 2025 This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer. The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs. The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024. GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.
Official summary by the Congressional Research Service, via Congress.gov.
Constitution Index
“VFA Constitution grade”
Constitutionally sound
Graded 2026-10-11
SI-generated grade · five published checks · not individually reviewed by a person · methodology
The bill is a constitutional exercise of federal power under the Commerce Clause and the Spending Clause, as it regulates interstate commerce in pharmaceuticals and conditions federal benefits on compliance. It does not infringe on any enumerated rights, respects individual sovereignty by incentivizing rather than mandating private conduct, and appropriately delegates implementation to federal agencies within their statutory authority. The bill does not consolidate decision-making beyond the necessary federal role in drug approval and interstate commerce, and it provides clear procedural mechanisms for the issuance of priority review vouchers and guidance, satisfying due process concerns.
-
✓ Passes · Enumerated powers
The federal government has authority to regulate the approval and marketing of drugs under the Commerce Clause (Article I, Section 8, Clause 3), as drugs are articles of interstate commerce. The bill also authorizes the FDA to issue priority review vouchers, which are a form of federal benefit or spending, permissible under the Spending Clause (Article I, Section 8, Clause 1). The bill does not ex… -
✓ Passes · Bill of Rights
The bill does not restrict speech, religion, assembly, press, petition, the right to bear arms, or any other right protected by the Bill of Rights. It imposes no searches or seizures, no self-incrimination, no deprivation of life, liberty, or property without due process, and no cruel or unusual punishment. The bill is purely regulatory and incentive-based, affecting only the conditions under whic… -
✓ Passes · Individual sovereignty
The bill does not restrict individual freedom. It encourages the development of pediatric cancer treatments by allowing combination trials and renewing a voucher program. It does not mandate any individual action, nor does it restrict what a person can do with their person, property, speech, labor, or belief. The burden of proof for any restriction is not triggered because there is no restriction. -
✓ Passes · Decentralization
The bill addresses a national issue—pediatric cancer drug development—that cannot be effectively handled by individuals, local communities, or states alone due to the interstate nature of pharmaceutical research and approval. The federal role is minimal and necessary to ensure uniform safety and efficacy standards across state lines. The bill does not consolidate decision-making upward beyond the … -
✓ Passes · Due process and takings
The bill does not take private property without just compensation. It does not deprive any person of life, liberty, or property without due process. The FDA's issuance of guidance and the voucher program are subject to existing administrative procedures that provide notice and opportunity for comment, satisfying procedural due process. The bill also requires reports to Congress, ensuring accountab…
Sources: Congress.gov: S 932 summary
Report an error in this grade
What should pass
“VFA SI Solution”
No solution yet
A sourced SI draft appears here once it passes automated checks (Constitution citation, source verification, independent SI critic). How publication works.
Related on VFA
For journalists and bloggers
“Embed this grade”
Free to use with the link back. The badge and card update when the grade changes. Embed terms →
